2021
1 November, 2021
FluoGuide initiates preclinical development with FG002
The initiation of the preclinical development of FG002 broadens FluoGuide’s portfolio of uPAR-targeted products with features...
12 October, 2021
Redeye initiates commissioned research on FluoGuide
Starting today, Redeye has initiated its commissioned research, meaning that Redeye will continuously monitor and analyze FluoGuide’s...
It is an important milestone for FluoGuide to now be able to demonstrate that FG001 is safe and well tolerated in patients undergoing...
14 September, 2021
Executive management members and members of the Board of Directors buys shares and board member Shomit Ghose sells shares
“Due to the success of FluoGuide, I have to pay tax on my shareholdings of FluoGuide and I have decided to finance this by selling...
FluoGuide is conducting a clinical phase I/II trial evaluating safety and efficacy of its lead asset, FG001, in patients with aggressive...
The ongoing clinical phase I/II trial with FG001 is designed as a two-phased trial, where the first phase aims to identify the optimal...
Summary *) Result per share (DKK per share): Operating result divided by the average number of shares during the period. The total...
Earlier this year the Company announced it had acquired worldwide exclusive rights to use FG001 for photothermal therapy. Now the first...
20 August, 2021
FluoGuide receives tranche of EUR 750,000 under its ongoing grant from EIC Accelerator - SME Instrument under European Union for FG001
Last year, the Company announced it was awarded with a grant on in total EUR 2.5 million under the European Innovation Council (EIC)...